BRISTOL-MYERS SQUIBB COMPANY (BMY) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 49.19B USD | |
| Cost of products and services | 14.68B USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $49.19B | $14.68B | (m) |
| 2026-03-31 | (m) | $48.48B | $14.32B | (m) |
| 2025-12-31 | (m) | $48.19B | $13.94B | (m) |
| 2025-09-30 | (m) | $48.03B | $14.65B | (m) |
| 2025-06-30 | (m) | $47.70B | $14.17B | (m) |
| 2025-03-31 | (m) | $47.64B | $14.07B | (m) |
| 2024-12-31 | (m) | $48.30B | $13.97B | (m) |
| 2024-09-30 | (m) | $47.44B | $11.90B | (m) |
| 2024-06-30 | (m) | $46.51B | $11.45B | (m) |
| 2024-03-31 | (m) | $45.53B | $11.06B | (m) |
| 2023-12-31 | (m) | $45.01B | $10.69B | (m) |
| 2023-09-30 | (m) | $44.94B | $10.54B | (m) |
| 2023-06-30 | (m) | $45.19B | $10.39B | (m) |
| 2023-03-31 | (m) | $45.85B | $10.23B | (m) |
| 2022-12-31 | (m) | $46.16B | $10.14B | (m) |
| 2022-09-30 | (m) | $46.74B | $9.90B | (m) |
| 2022-06-30 | (m) | $47.14B | $9.84B | (m) |
| 2022-03-31 | (m) | $46.96B | $9.57B | (m) |
| 2021-12-31 | (m) | $46.38B | $9.94B | (m) |
| 2021-09-30 | (m) | $45.47B | $10.49B | (m) |
| 2021-06-30 | (m) | $44.38B | $10.71B | (m) |
| 2021-03-31 | (m) | $42.81B | $10.95B | (m) |
| 2020-12-31 | $30.75B | $42.52B | $11.77B | 72.31% |
| 2020-09-30 | (m) | $39.40B | $11.36B | (m) |
| 2020-06-30 | (m) | $34.86B | $10.64B | (m) |
| 2020-03-31 | (m) | $31.01B | $9.92B | (m) |
| 2019-12-31 | $18.07B | $26.14B | $8.08B | 69.10% |
| 2019-09-30 | (m) | $24.17B | $7.34B | (m) |
| 2019-06-30 | (m) | $23.86B | $7.17B | (m) |
| 2019-03-31 | (m) | $23.29B | $6.81B | (m) |
| 2018-12-31 | $16.01B | $22.56B | $6.55B | 70.98% |
| 2018-09-30 | (m) | $22.04B | (m) | (m) |
| 2018-06-30 | (m) | $21.60B | (m) | (m) |
| 2018-03-31 | (m) | $21.04B | (m) | (m) |
| 2017-12-31 | $14.71B | $20.78B | (m) | 70.80% |
| 2017-09-30 | (m) | $20.57B | (m) | (m) |
| 2017-06-30 | (m) | $20.24B | (m) | (m) |
| 2017-03-31 | (m) | $19.96B | (m) | (m) |
| 2016-12-31 | $14.48B | $19.43B | (m) | 74.54% |
| 2016-09-30 | (m) | $18.47B | (m) | (m) |
| 2016-06-30 | (m) | $17.62B | (m) | (m) |
| 2016-03-31 | (m) | $16.91B | (m) | (m) |
| 2015-12-31 | $12.65B | $16.56B | (m) | 76.39% |
| 2015-09-30 | (m) | $16.53B | (m) | (m) |
| 2015-06-30 | (m) | $16.38B | (m) | (m) |
| 2015-03-31 | (m) | $16.11B | (m) | (m) |
| 2014-12-31 | $11.95B | $15.88B | (m) | 75.24% |
| 2014-09-30 | (m) | $16.06B | (m) | (m) |
| 2014-06-30 | (m) | $16.21B | (m) | (m) |
| 2014-03-31 | (m) | $16.36B | (m) | (m) |
| 2013-12-31 | $11.77B | $16.39B | (m) | 71.81% |
| 2013-09-30 | (m) | $16.14B | (m) | (m) |
| 2013-06-30 | (m) | $15.81B | (m) | (m) |
| 2013-03-31 | (m) | $16.20B | (m) | (m) |
| 2012-12-31 | $13.01B | $17.62B | (m) | 73.84% |
| 2012-09-30 | (m) | $18.88B | (m) | (m) |
| 2012-06-30 | (m) | $20.49B | (m) | (m) |
| 2012-03-31 | (m) | $21.48B | (m) | (m) |
| 2011-12-31 | $15.65B | $21.24B | (m) | 73.65% |
| 2011-09-30 | (m) | $20.90B | (m) | (m) |
| 2011-06-30 | (m) | $20.35B | (m) | (m) |
| 2011-03-31 | (m) | $19.69B | (m) | (m) |
| 2010-12-31 | $14.21B | $19.48B | (m) | 72.92% |
| 2010-09-30 | (m) | $19.41B | (m) | (m) |
| 2010-06-30 | (m) | $19.40B | (m) | (m) |
| 2010-03-31 | (m) | $19.29B | (m) | (m) |
| 2009-12-31 | (m) | $18.81B | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $17.71B | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | $15.62B | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |